Innate Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jonathan Dickinson
Chief executive officer
€435.2k
Total compensation
| CEO salary percentage | 21.06% |
| CEO tenure | 1.2yrs |
| CEO ownership | n/a |
| Management average tenure | 2.5yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Nov 17
Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing
Jul 19
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings.News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Apr 02Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%
Feb 22Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Dec 20Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
Oct 24Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
May 21Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 24Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Sep 30Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 16Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Mar 30Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic
Dec 18Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?
Sep 27Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year
Aug 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -€46m |
| Mar 31 2025 | n/a | n/a | -€48m |
| Dec 31 2024 | €435k | €92k | -€49m |
Compensation vs Market: Jonathan's total compensation ($USD509.78K) is about average for companies of similar size in the French market ($USD530.73K).
Compensation vs Earnings: Insufficient data to compare Jonathan's compensation with company performance.
CEO
Jonathan Dickinson (57 yo)
Mr. Jonathan E. Dickinson, MBA, BSc served as Executive Vice President and General Manager of Europe at Incyte Corp. since June 2019 until October 2024. Mr. Dickinson is Chief Executive Officer of Innate P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.2yrs | €435.25k | no data | |
| Executive VP & COO | 2yrs | €709.79k | 0.36% € 519.6k | |
| Executive VP & Chief Medical Officer | 1yr | €770.50k | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Senior VP & CFO | 4.8yrs | no data | 0.038% € 55.3k | |
| Vice President of Investor Relations | 1yr | no data | no data | |
| Vice President of Compliance | 7yrs | no data | 0.094% € 134.8k | |
| VP of Legal & Corporate Affairs and Secretary of the Supervisory Board | 3yrs | no data | 0.028% € 40.2k | |
| Vice President of Human Resources & Social Relations | 6yrs | no data | 0.069% € 99.6k |
Experienced Management: IPH's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | €435.25k | no data | |
| Strategic Advisory Board Member | 7.2yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Strategic Advisory Board Member | 2yrs | no data | no data | |
| Independent Director | less than a year | €52.00k | 0.0027% € 3.9k | |
| Independent Chairwoman of the Board | less than a year | €100.00k | 0.027% € 39.3k | |
| Independent Vice Chairperson of the Board | less than a year | €64.00k | 0.0011% € 1.6k | |
| Chairman of Strategic Advisory Board | 7.2yrs | no data | no data | |
| Independent Director | less than a year | €53.00k | 0.00072% € 1.0k | |
| Strategic Advisory Board Member | 2yrs | no data | no data | |
| Strategic Advisory Board Member | 7.2yrs | no data | no data |
Experienced Board: IPH's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 08:01 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innate Pharma S.A. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Yigal Nochomovitz | Citigroup Inc |
| Michael Thomas Cooper | Edison Investment Research |